CD274 and neoplasm: Several biomarkers have been developed for predicting the benefit of ICI therapy for melanoma patients, including PD-L1 expression (16), tumor mutation burden (TMB) (17), interferon-γ signal (18, 19), and tumor infiltrating lymphocytes (TILs) (20).